Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
Myeloid Therapeutics
Genentech, Inc.
Jonsson Comprehensive Cancer Center
IDEAYA Biosciences
Innate Pharma
Pfizer
Incyte Corporation
Pfizer
Tempest Therapeutics
Nurix Therapeutics, Inc.
Pfizer
Exelixis
Jonsson Comprehensive Cancer Center
Xencor, Inc.
University of Virginia
Incyte Corporation
NextPoint Therapeutics, Inc.
Monopar Therapeutics
Monopar Therapeutics
Kinnate Biopharma
Bristol-Myers Squibb
Orion Biotechnology Polska Sp. z o.o.
Carisma Therapeutics Inc
Zumutor Biologics Inc.
Molecular Templates, Inc.
Inhibrx Biosciences, Inc
RemeGen Co., Ltd.
Eli Lilly and Company
Pfizer
Xencor, Inc.
Pliant Therapeutics, Inc.
Aurigene Discovery Technologies Limited
University of Florida
Fate Therapeutics
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Herlev Hospital
Xencor, Inc.
Ludwig Institute for Cancer Research
Genocea Biosciences, Inc.
Incyte Corporation
Incyte Corporation
Celgene
Merrimack Pharmaceuticals